Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 76

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 76
---
 one-third of the shares of common stock underlying the RSUs vesting on the first, second and third anniversaries of the grant date, subject to continued service. |

| (3) | Effective March 1, 2025, our compensation & people committee, or board of directors, as applicable, approved the grant of these PSUs to our NEOs. The PSUs vest as to one-quarter (or one-half as it relates to our chief executive officer) of the underlying shares of common stock upon the achievement of a specified clinical related milestone, as to an additional one-quarter of the underlying shares of common stock upon the achievement of a second specified clinical related milestone and as to one-half (or one-quarter as it relates to the chief executive officer) of the underlying shares of common stock upon the achievement of a third specified research and development milestone, in each case subject to continued service. |

| (4) | Increase reflects merit-based adjustment. |

| (5) | Increase reflects merit- and market-based adjustments. |

Salary increases for 2025 became effective as of January 1, 2025. The annual cash incentive target award percentage for our NEOs remained unchanged from 2024. Annual performance-based cash incentive program payouts for 2025 annual cash incentives will be based on our performance against specific research, clinical, operational and financial company goals and, as stated above, will be capped at 150% of the target payout level. 56

In February 2025, our compensation & people committee determined that annual equity awards for our NEOs, with the exception of our chief executive officer, would be split approximately 50% in stock options, 25% in RSUs and 25% in PSUs, based on grant date fair value, for 2025, in order to closely align executive compensation with the achievement of meaningful corporate milestones. The compensation & people committee and board of directors determined that the grant of the annual equity award for our chief executive officer would be split approximately 40% in stock options, 20% in RSUs and 40% in PSUs based on grant date fair value, in order to further emphasize the performance-based component. Supplemental 2025 Equity Grants In addition to the annual equity grants outlined above, in February 2025, the compensation & people committee granted to Mr. Burns and Ms. Jones the RSUs set forth in the table below, effective March 1, 2025, in order to recognize their contributions to the company’s sale of